|
(1) Salvia, Panax traditional Chinese medicine for the treatment of cardiovascular disease, the two often compatibility. Salvianolic acids and Panax notoginseng saponins inhibit platelet aggregation activity, respectively, for the study of the main active component compares the two substances alone and in combination in SD rats in vitro and in vivo platelet aggregation rate. In vitro experiments showed that salvianolic acids, PNS could inhibit platelet ADP-induced rat washed platelets and platelet-rich plasma (PRP) gathered, but no synergistic effect. 550mg · kg -1 intragastrically administered after 5d the salvianolic acids PNS could significantly inhibit the aggregation of platelets (PRP) in rats ADP-induced platelet rich plasma PRP aggregation, salvianolic acids PNS ratio of 5:1, synergistic anti-ADP-induced rats. Also studied Salvia strongest monomer composition salvianolic acid B, and found that it can significantly inhibit ADP-induced aggregation of rat washed platelets IC 50 67.33 ± 1.22μg · mL < sup> -1 . (2) In order to further clarify the salvianolic acids, PNS, Sal B inhibited ADP-induced platelet aggregation mechanism, the experimental set up salvianolic acids, PNS, salvianolic acid B treatment before and after dimensional electrophoresis profiles of total platelet proteins using MALDI-TOF-MS technology to identify and identification of differentially expressed proteins between two different groups of platelet protein. These differentially expressed protein and calcium balance, platelet activation, cell transmembrane signal transduction, the material energy metabolism, antioxidant systems and is closely related to the cytoskeleton, and applied by Western blot validation of partial differential protein expression levels. (3) using HPLC-UV, salvianolic acids Panax notoginseng saponins combined (5:1) in rat plasma after intragastric administration of protocatechuic aldehyde, rosmarinic acid, purple oxalic acid, salvianolic acid B The content of simultaneous determination of the method and its pharmacokinetic study. Column: Zorbax SB-C 18 column (250mm × 4.6mm, 5μm); flow rate: 1 mL · min . -1 ; column temperature: 30 ° C; detection wavelength: 280nm, gradient elution of acetonitrile and 0.026% aqueous phosphoric acid solution, plasma samples to a volume fraction of 10% hydrochloric acid, then extracted twice with ethyl acetate, and according to the measurement result calculating the main pharmacokinetic parameters. As a result, the four components of the days during the day RSD of% were less than 15%, the extraction recoveries were greater than 70%, a good linear relationship (r> 0.99). Protocatechuic aldehyde the 10.0min Tmax, C , max for 6.466μg · mL -1 , AUC 0-240 value 82.0μg · min · mL -1 , rosemary acid 11.7min peak, C , max for 10.50μg · mL -1 , the AUC 0-240 value 446.6μg · min · mL -1 , the lithospermate 20.8min peak, C max 5.950μg · mL -1 , the the AUC 0-240 value 486.7μg · min · mL -1 8.33min peak, salvianolic acid B, C max for 48.12μg · mL -1 , the AUC , 0-240 value 1766μg · min · mL -1 . (4) the use of HPLC-UV assay Rats were given salvianolic acids and PNS (5:1) 5 ~ 240min within 11 points of protocatechuic aldehyde, rosmarinic acid, lithospermate salvianolic acid B content in the organs of the organizations, summed up the difference and characteristics. The results show that only protocatechuic aldehyde in the liver, spleen, lung, kidney tissue was detected protocatechuic aldehyde rapid absorption peak content, which amounts to 10 ~ 30min after drug content with time quickly reduce ; the curve when lung tissue of protocatechuic aldehyde drugs bimodal phenomenon. The plasma drug concentration of the content of the drug in the tissue is much lower than that of the same time.
|